Trial status: This phase III clinical trial is complete, with preliminary negative results at six months.

Trial name: TREND-HD

FDA phase: Phase III

Sponsor: Amarin Corporation

Trial design: A 6-month, double-blind, randomized, placebo-controlled trial, studying 316 HD patients over the age of 35 who have early stages of HD. For the first 6 months, participants were divided into two groups, one taking 2 grams of the drug every day, and the other group taking placebo. During the second follow-up 6 months, all participants took the study drug.

Outcome measures: Total motor comparison after 6 months of drug treatment; also, measures of cognitive and functional capacity.

Location: 43 sites

Results: No motor or other improvement was seen at the end of the six month trial.